CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 13 enrolled
Drug / intervention
Quantra Analyzerdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04301193
NCT04301193N/ACompleted
CompareCT.gov

Efficacy of Sonorheometry Point of the Care Device in Determining Low Fibrinogen Levels in Pregnant Blood: an Invitro Dilution and Reconstitution Study

University of Maryland, Baltimore·observational·Posted Mar 10, 2020·Updated Apr 27, 2025

In Brief

An observational study evaluating Quantra Analyzer for Hemorrhage and Coagulation Delay. Completed, enrolled 13 participants across 1 site.

Detailed Summary

In this study the investigators will evaluate a new point of care Quantra Hemostasis Analyzer system to assess coagulation rapidly with ease.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHemorrhage, Coagulation Delay
CountriesUnited States
CollaboratorsHemoSonics LLC

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMar 10, 2020
Enrollment StartNov 1, 2019
Primary CompletionJul 31, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.3 years ago

Interventions

Quantra Analyzerdevice

Subject's blood samples will be manipulated in the lab and will be tested with the Quantra Analyzer. After obtaining blood from each patient, the blood was diluted to varying dilutions to obtain different fibrinogen concentrations. This way, 89 samples were prepared from the blood from 13 patients. Each sample was analyzed for fibrinogen concentration in the lab using conventional technology. Additionally each sample was used to measure Quantra variables such as clot stiffness (CS), and fibrinogen contribution to clot stiffness (FCS).